panel-discussion
As more and more platforms and instruments come to play in the biomarker research, the method development and validation for biomarkers become more and more complex. Best regulatory practice in analyzing biomarkers to support drug development is expected, but deciding which regulation to follow has not been consistent.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.